Literature DB >> 2820358

Steroid therapy in multiple sclerosis. Point of view.

R Troiano, S D Cook, P C Dowling.   

Abstract

A number of studies have demonstrated that high-dose corticosteroid treatment improves the rate of recovery from acute exacerbations of multiple sclerosis. The beneficial effect is more rapidly and consistently produced by high-dose corticosteroid administration than with adrenocorticotropic hormone. The most rapid improvement in clinical condition and cerebrospinal fluid parameters of patients has been observed with short courses of very high-dose intravenous therapy. This form of treatment would be most advantageous for patients with severe and rapidly progressive exacerbations. Ultimately, the duration of treatment will depend on the patient's response to treatment, tolerance of corticosteroid withdrawal, and the occurrence of significant complications of therapy. However, in our experience, a three- to four-month slowly tapered course of oral therapy is often needed, and is usually well tolerated, with few serious side effects when given once daily in the morning.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2820358     DOI: 10.1001/archneur.1987.00520200007008

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  9 in total

1.  Fulminant monophasic multiple sclerosis, Marburg's type.

Authors:  M D Johnson; P Lavin; W O Whetsell
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-10       Impact factor: 10.154

2.  Pathological yawning as a symptom of multiple sclerosis.

Authors:  T Postert; D Pöhlau; S Meves; I Nastos; H Przuntek
Journal:  J Neurol       Date:  1996-03       Impact factor: 4.849

3.  One-year MR imaging follow-up of patients with multiple sclerosis under cortisone therapy.

Authors:  D Uhlenbrock; E Herbe; D Seidel; W Gehlen
Journal:  Neuroradiology       Date:  1989       Impact factor: 2.804

Review 4.  Role of steroids and immunosuppression and effects of interferon beta-1b in multiple sclerosis.

Authors:  D E Goodkin
Journal:  West J Med       Date:  1994-09

5.  Short-term high dose steroid therapy does not affect the hypothalamic-pituitary-adrenal axis in relapsing multiple sclerosis patients. Clinical assessment by the insulin tolerance test.

Authors:  Z Lević; D Micić; J Nikolić; N Stojisavljević; D Sokić; S Janković; A Kendereski; M Mavra
Journal:  J Endocrinol Invest       Date:  1996-01       Impact factor: 4.256

Review 6.  Newer versus older treatments for relapsing-remitting multiple sclerosis.

Authors:  B Weinstock-Guttman; J A Cohen
Journal:  Drug Saf       Date:  1996-02       Impact factor: 5.606

7.  Immunomodulation in the treatment of multiple sclerosis and amyotrophic lateral sclerosis: a model for autoimmune disorders.

Authors:  K Alonso; R Medenica
Journal:  J Natl Med Assoc       Date:  1995-08       Impact factor: 1.798

8.  Patient-reported adverse effects of high-dose intravenous methylprednisolone treatment: a prospective web-based multi-center study in multiple sclerosis patients with a relapse.

Authors:  Peter Joseph Jongen; Ioanna Stavrakaki; Bernard Voet; Erwin Hoogervorst; Erik van Munster; Wim H Linssen; Ludovicus G Sinnige; Wim I Verhagen; Leo H Visser; Ruud van der Kruijk; Freek Verheul; Jan Boringa; Marco Heerings; Werner Gladdines; Fredrik Lönnqvist; Pieter Gaillard
Journal:  J Neurol       Date:  2016-06-07       Impact factor: 4.849

9.  The Impact of Immunomodulatory Treatment on Kappa Free Light Chains as Biomarker in Neuroinflammation.

Authors:  Franz Felix Konen; Ulrich Wurster; Torsten Witte; Konstantin Fritz Jendretzky; Stefan Gingele; Hayrettin Tumani; Kurt-Wolfram Sühs; Martin Stangel; Philipp Schwenkenbecher; Thomas Skripuletz
Journal:  Cells       Date:  2020-03-31       Impact factor: 6.600

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.